Lisata Therapeutics (NASDAQ:LSTA) Stock Rating Upgraded by Zacks Research

Lisata Therapeutics (NASDAQ:LSTA) was upgraded by research analysts at Zacks Research to a “hold” rating in a report issued on Monday,Zacks.com reports.

LSTA has been the topic of several other reports. cut Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright cut Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $15.00.

Lisata Therapeutics Stock Performance

Shares of LSTA stock opened at $3.12 on Monday. Lisata Therapeutics has a 1 year low of $1.81 and a 1 year high of $5.07. The stock has a market cap of $28.42 million, a PE ratio of -1.68 and a beta of 0.81. The business’s fifty day moving average is $4.19 and its 200-day moving average is $3.37.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter. Equities research analysts predict that Lisata Therapeutics will post -1.09 earnings per share for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its stake in shares of Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after acquiring an additional 7,093 shares in the last quarter. SOL Capital Management CO acquired a new stake in shares of Lisata Therapeutics in the first quarter worth $61,000. Cerity Partners LLC acquired a new stake in shares of Lisata Therapeutics in the second quarter worth $32,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Lisata Therapeutics in the third quarter worth $37,000. Finally, Ground Swell Capital LLC boosted its position in shares of Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after buying an additional 15,213 shares during the period. 8.94% of the stock is owned by institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.